[go: up one dir, main page]

CU20160008A7 - Métodos para controlar los niveles de fucosilacion en proteinas - Google Patents

Métodos para controlar los niveles de fucosilacion en proteinas

Info

Publication number
CU20160008A7
CU20160008A7 CUP2016000008A CU20160008A CU20160008A7 CU 20160008 A7 CU20160008 A7 CU 20160008A7 CU P2016000008 A CUP2016000008 A CU P2016000008A CU 20160008 A CU20160008 A CU 20160008A CU 20160008 A7 CU20160008 A7 CU 20160008A7
Authority
CU
Cuba
Prior art keywords
proteins
fucosilation
levels
methods
control
Prior art date
Application number
CUP2016000008A
Other languages
English (en)
Other versions
CU24312B1 (es
Inventor
Pradip Nair
Ramakrishnan Melarkode
Rasika Venkataraman
Laxmi Adhikary
Ankur Bhatnagar
Sunaina Prabhu
Kriti Shukla
Dinesh Baskar
Saravanan Desan
Haris Venkatraman Pai
Casimiro José Enrique Montero
Original Assignee
Biocon Ltd
Ct De Inmunología Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd, Ct De Inmunología Molecular filed Critical Biocon Ltd
Publication of CU20160008A7 publication Critical patent/CU20160008A7/es
Publication of CU24312B1 publication Critical patent/CU24312B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

La presente invención se relaciona con un método o procedimiento para controlar, inhibir o reducir la fucosilación de proteínas en un eucariota y/o sistema de expresión de proteínas eucariota. Dicho método comprende llevar a cabo la expresión de proteína y/o modificación post-traduccional en presencia de una elevada concentración de manganeso o de iones de manganeso.
CUP2016000008A 2013-07-23 2014-07-23 Métodos para controlar los niveles de fucosilación en proteínas CU24312B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3262CH2013 2013-07-23
IN3265CH2013 2013-07-23
PCT/IB2014/063348 WO2015011660A1 (en) 2013-07-23 2014-07-23 Methods for controlling fucosylation levels in proteins

Publications (2)

Publication Number Publication Date
CU20160008A7 true CU20160008A7 (es) 2016-11-29
CU24312B1 CU24312B1 (es) 2018-02-08

Family

ID=52392808

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2016000008A CU24312B1 (es) 2013-07-23 2014-07-23 Métodos para controlar los niveles de fucosilación en proteínas

Country Status (19)

Country Link
US (2) US9856502B2 (es)
EP (2) EP3024922A4 (es)
JP (1) JP6480926B2 (es)
KR (1) KR102062784B1 (es)
CN (1) CN105392878A (es)
AU (1) AU2014294618B2 (es)
BR (1) BR112016001461A2 (es)
CA (1) CA2926967C (es)
CU (1) CU24312B1 (es)
EA (1) EA201690269A1 (es)
HK (1) HK1220228A1 (es)
MX (1) MX2016001042A (es)
NZ (1) NZ716182A (es)
PE (1) PE20160218A1 (es)
PH (1) PH12016500158A1 (es)
SG (1) SG11201600067YA (es)
TW (1) TWI621711B (es)
WO (1) WO2015011660A1 (es)
ZA (1) ZA201601113B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524233B2 (en) 2008-03-14 2013-09-03 Biocon Limited & Centro de Immunologia Molecular Monoclonal antibody and a method thereof
KR102623965B1 (ko) 2014-12-01 2024-01-11 암젠 인크 당단백질의 글리칸 함량 수준을 조작하는 방법
ES2991182T3 (es) * 2016-10-21 2024-12-02 Biocon Ltd Un anticuerpo monoclonal y un método de uso para el tratamiento del lupus
AU2017360807B2 (en) * 2016-11-18 2024-11-28 Biocon Limited Rapid and efficient de-glycosylation of glycoproteins
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
CN111954719B (zh) 2018-03-26 2025-07-18 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型
KR102742590B1 (ko) * 2018-04-20 2024-12-16 (주)셀트리온 당단백질의 푸코실레이션을 조절하는 방법
CN112752769B (zh) * 2018-08-10 2024-12-10 豪夫迈·罗氏有限公司 用于调节蛋白糖基化的细胞培养策略
HU231514B1 (hu) 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
SG11202104092UA (en) * 2018-11-13 2021-05-28 Janssen Biotech Inc Control of trace metals during production of anti-cd38 antibodies
JP7469593B2 (ja) * 2018-12-27 2024-04-17 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体を製造する方法
CN112779307B (zh) * 2021-01-11 2022-04-19 苏州药明生物技术有限公司 一种两阶段调节cho表达外源蛋白糖型的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
WO1998043089A1 (en) * 1997-03-03 1998-10-01 Bristol-Myers Squibb Company Monoclonal antibodies to human cd6
WO2003073843A2 (en) 2002-03-05 2003-09-12 Artemis Pharmaceuticals Gmbh Inbred embryonic stem-cell derived mice
AU2006255085A1 (en) 2005-06-03 2006-12-14 Genentech, Inc. Method of producing antibodies with modified fucosylation level
WO2007070315A2 (en) 2005-12-08 2007-06-21 Amgen Inc. Improved production of glycoproteins using manganese
US7846724B2 (en) * 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
US8524233B2 (en) * 2008-03-14 2013-09-03 Biocon Limited & Centro de Immunologia Molecular Monoclonal antibody and a method thereof
WO2010141855A1 (en) 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
BR112012025645A2 (pt) * 2010-04-07 2017-12-12 Momenta Pharmaceuticals Inc glicanos de alta manose.
EP2809773B1 (en) * 2012-01-30 2020-09-02 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition

Also Published As

Publication number Publication date
EA201690269A1 (ru) 2016-05-31
SG11201600067YA (en) 2016-02-26
AU2014294618B2 (en) 2019-06-27
CA2926967A1 (en) 2015-01-29
EP4282975A2 (en) 2023-11-29
KR102062784B1 (ko) 2020-01-07
CN105392878A (zh) 2016-03-09
EP3024922A1 (en) 2016-06-01
HK1220228A1 (zh) 2017-04-28
JP6480926B2 (ja) 2019-03-13
WO2015011660A1 (en) 2015-01-29
MX2016001042A (es) 2017-01-05
ZA201601113B (en) 2017-08-30
NZ716182A (en) 2018-07-27
BR112016001461A2 (pt) 2017-08-29
US20160138065A1 (en) 2016-05-19
CU24312B1 (es) 2018-02-08
KR20160036589A (ko) 2016-04-04
EP3024922A4 (en) 2017-03-29
PE20160218A1 (es) 2016-05-09
US9856502B2 (en) 2018-01-02
JP2016525352A (ja) 2016-08-25
TWI621711B (zh) 2018-04-21
AU2014294618A1 (en) 2016-02-11
US10308970B2 (en) 2019-06-04
TW201512396A (zh) 2015-04-01
EP4282975A3 (en) 2024-02-28
CA2926967C (en) 2020-12-08
PH12016500158A1 (en) 2016-04-25
US20180087080A1 (en) 2018-03-29

Similar Documents

Publication Publication Date Title
CU20160008A7 (es) Métodos para controlar los niveles de fucosilacion en proteinas
BR112018004887A2 (pt) sistemas e métodos de controle de potência.
EP3262572A4 (en) Techniques of oscillator control for quantum information processing and related systems and methods
BR112014029884A2 (pt) sistemas de controle e método.
BR112013032042A2 (pt) dispositivos e métodos de recepção e de difusão, programa, sistema de controle do aplicativo de ligação
EP3028100A4 (en) Application specific, dual mode projection system and method
EP2984346A4 (en) Water booster control system and method
BR112013032215A2 (pt) método e sistema para processamento de consultas de saldo de contas financeiras
BR112013032183A2 (pt) sistema e método de avaliação de recursos
EP2978559A4 (en) Laser welding system and method
EP4327660A3 (en) Selective weed control using d-napropamide
MX2015012428A (es) Tratamiento contra enfermedades mediadas th2 por inhibicion de bromodominios.
WO2014197885A3 (en) Inhibitors of complement factor h
EP3066270A4 (en) Sewer system, and method of controlling it
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
EP3234887A4 (en) Intelligent system and method of payment, finance, and social commerce
EP3088411A4 (en) Method for purifying antibody having low isoelectric point
EP3018756A4 (en) Tracking system, tracking method, and program
WO2014130741A3 (en) Nme inhibitors and methods of using nme inhibitors
CL2016000351A1 (es) Método para la cuantificación de actinio-227 en composiciones de radio-223.
TN2015000414A1 (en) Proteins specific for baff and b7rp1 and uses thereof
EP2959462A4 (en) Automated beverage generating system and method of operating the same
SG11201509164XA (en) System and method of programming an energized ophthalmic lens
EP2816355B8 (de) Detektionsverfahren zur Detektion von Bakterien, Verfahren zur Herstellung von Fusionsproteinen und Fusionsprotein
CL2015002080A1 (es) Métodos de control selectivo de malezas